Your browser doesn't support javascript.
loading
Long-term response to crizotinib in a 17-year-old boy with treatment-naïve ALK-positive non-small-cell lung cancer.
Megaro, Giacomina; Miele, Evelina; Spinelli, Gian Paolo; Alessi, Iside; Del Baldo, Giada; Cozza, Raffaele; Russo, Ida; De Pasquale, Maria Debora; Cefalo, Maria Giuseppina; Tomà, Paolo; Carai, Andrea; Di Ruscio, Valentina; De Ioris, Maria Antonietta; Mastronuzzi, Angela.
Afiliação
  • Megaro G; Department of Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Miele E; Department of Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Spinelli GP; UOC Oncologia Universitaria, ASL Latina (distretto Aprilia), Sapienza University of Rome- Aprilia, Latina, Italy.
  • Alessi I; Department of Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Del Baldo G; Department of Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Cozza R; Department of Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Russo I; Department of Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • De Pasquale MD; Department of Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Cefalo MG; Department of Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Tomà P; Department of Imaging, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Carai A; Neurosurgery Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Di Ruscio V; Department of Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • De Ioris MA; Department of Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Mastronuzzi A; Department of Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Cancer Rep (Hoboken) ; 5(3): e1483, 2022 03.
Article em En | MEDLINE | ID: mdl-35092185
ABSTRACT

BACKGROUND:

Lung cancer is the leading cause of cancer-related death. NSCLC accounts for 80-90% of cases. In young patients, adenocarcinoma is the most frequent histotype and 3-7% expresses the rearrangement of ALK oncogene, sensitive to TKIs. Crizotinib is the first ALK inhibitor approved by the FDA. CASE We present a case of a 17-year-old male with metastatic treatment-naïve ALK-positive adenocarcinoma. He was treated with crizotinib and obtained a prolonged response with PFS of 33 months.

CONCLUSION:

Crizotinib can be extremely effective in adolescents with treatment-naïve ALK-positive NSCLC but fail to prevent a central nervous system relapse. Resistance mechanisms need to be investigated.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Limite: Adolescent / Humans / Male Idioma: En Revista: Cancer Rep (Hoboken) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Limite: Adolescent / Humans / Male Idioma: En Revista: Cancer Rep (Hoboken) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália